Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased ...

Ozempic and similar weight loss drugs offer major benefits for obesity and heart health, but side effects, muscle loss, and ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity or type 2 diabetes receiving semaglutide have a lower risk for suicidal ideation than those ...

A new study suggests that some people taking the popular weight-loss drug Semaglutide may face an unexpected downside: loss of muscle. Older adults and women seem to be at greater risk, but ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults prescribed semaglutide were more likely to ...

Novo Nordisk (CPSE:NOVO B) has used legal and regulatory pressure to push Hims & Hers to drop plans for a compounded oral ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) in patients with ...

Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than previously reported. Using the specific ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) and oral semaglutide (Rybelsus®). Injections are usually more ...

Taking semaglutide, the active ingredient in drugs like Wegovy and Ozempic used for weight loss, can help boost heart health in people without diabetes, according to new research. In a study of over ...

The intake of oral semaglutides such as Wegovy or Rybelsus among adults with type 2 diabetes (T2D) was associated with a reduced risk of heart failure (HF) compared to those who took a placebo, ...

Semaglutide linked to 40-70% lower risk of first-time Alzheimer’s diagnosis in type 2 diabetes patients compared to other antidiabetic medications. Study: Associations of semaglutide with first-time ...